0000888491-21-000024.txt : 20211104 0000888491-21-000024.hdr.sgml : 20211104 20211104165038 ACCESSION NUMBER: 0000888491-21-000024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEGA HEALTHCARE INVESTORS INC CENTRAL INDEX KEY: 0000888491 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383041398 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11316 FILM NUMBER: 211380763 BUSINESS ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 8-K 1 ohi-20211104x8k.htm 8-K
0000888491false00008884912021-11-042021-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​ ​​ ​

FORM 8-K

​ ​​ ​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2021

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

Maryland

1-11316

38-3041398

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

303 International Circle,

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

(410) 427-1700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act.

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value

OHI

New York Stock Exchange

Item 2.02     Regulation FD Disclosure

On November 4, 2021, Omega Healthcare Investors, Inc. (“Omega”) issued a press release regarding its financial results for the quarter ended September 30, 2021. Omega’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01     Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description of Exhibit

99.1Press release issued by the Company on November 4, 2021.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OMEGA HEALTHCARE INVESTORS, INC.

(Co-Registrant)

Dated: November 4, 2021

By:

/s/ Gail D. Makode

Gail D. Makode

Chief Legal Officer, General Counsel

EX-99.1 2 ohi-20211104ex99119fc24.htm EX-99.1

Exhibit 99.1

Graphic

303 International Circle P: 410.427.1700

Suite 200 F: 410.427.8800

Hunt Valley, MD 21030

PRESS RELEASE – FOR IMMEDIATE RELEASE

OMEGA REPORTS THIRD QUARTER 2021 RESULTS AND RECENT DEVELOPMENTS

Completed $172 Million in Real Estate Investments

HUNT VALLEY, MARYLAND – November 4, 2021 – Omega Healthcare Investors, Inc. (NYSE: OHI) (the “Company” or “Omega”) announced today its results for the quarter ended September 30, 2021.  The Company reported net income for the quarter of $142.8 million or $0.58 per common share.  The Company also reported Nareit Funds From Operations (“Nareit FFO”) for the quarter of $180.7 million or $0.73 per common share, Adjusted Funds From Operations (“Adjusted FFO” or “AFFO”) of $208.8 million or $0.85 per common share, and Funds Available for Distribution (“FAD”) of $198.8 million.

Nareit FFO, AFFO and FAD are supplemental non-GAAP financial measures that the Company believes are useful in evaluating the performance of real estate investment trusts.  For more information regarding these non-GAAP measures, see the “Funds From Operations” on the Company’s website at www.omegahealthcare.com.

CEO COMMENTS

Taylor Pickett, Omega’s Chief Executive Officer, stated, “Facility occupancy continued to improve in the quarter but still sits meaningfully below pre-pandemic levels, and as a result, many operators continue to rely on federal and state government support.  While an additional allocation of federal support was announced in the third quarter, it remains to be seen whether this will be sufficient to fund operator obligations through this continuing pandemic.”

Mr. Pickett continued, “Although we reported strong third quarter adjusted FFO and FAD, these results include approximately $16 million of revenue recognized by applying security deposits, letters of credit and collateral to Agemo and Gulf Coast’s contractual obligations.  When this collateral is exhausted and if these tenants continue not to pay rent, we expect that this would reduce our near-term adjusted FFO and FAD financial results.”

Mr. Pickett concluded, “As we have throughout this crisis, we would like to highlight the incredible efforts of our operators and their heroic employees, who continue to work tirelessly to bravely protect and care for their residents.”

2021 RECENT DEVELOPMENTS AND THIRD QUARTER HIGHLIGHTS

In Q4 2021, the Company…

declared a $0.67 per share quarterly cash dividend on common stock.

In Q3 2021, the Company…

completed $66 million of mortgage loan investments.
invested $96 million in capital renovation and construction-in-progress projects.
completed $10 million of real estate acquisitions.
sold 15 facilities for $110 million in cash proceeds, generating a $56 million gain.
paid a $0.67 per share quarterly cash dividend on common stock.

In Q2 2021, the Company…

collected over 99% of contractual rent and mortgage payments.
entered into a new $1.45 billion unsecured credit facility.
entered into a new $50 million term loan.
implemented a new $1.0 billion ATM program.
completed $6 million of mortgage loan investments.
sold six facilities for $13 million in cash proceeds, generating a $4 million gain.
invested $31 million in capital renovation and construction-in-progress projects.
paid a $0.67 per share quarterly cash dividend on common stock.

In Q1 2021, the Company…

collected over 99% of contractual rent and mortgage payments.
issued $700 million aggregate principal amount of 3.250% Senior Notes due 2033.
repurchased $350 million aggregate principal amount of 4.375% Senior Notes due 2023.
completed $595 million of real estate acquisitions.
sold 24 facilities for $188 million in cash proceeds, generating a $100 million gain.
invested $17 million in capital renovation and construction-in-progress projects.
Inspīr Carnegie Hill (Upper East Side, Manhattan) opens doors to residents.
paid a $0.67 per share quarterly cash dividend on common stock.
was included in the 2021 Bloomberg Gender-Equality Index.

NET INCOME

The Company reported net income of $142.8 million, or $0.58 per common share, on revenues of $281.7 million for the quarter ended September 30, 2021. This compares to a net loss of ($93.8) million, or ($0.40) per common share, on revenues of $119.2 million, for the same period in 2020.

For the nine months ended September 30, 2021, the Company reported net income of $394.1 million, or $1.62 per common share, on revenues of $812.9 million. This compares to net income of $100.5 million, or $0.43 per common share, on revenues of $628.6 million, for the same period in 2020.

The year-over-year increase in net income for the nine-month period ended September 30 was primarily due to (i) a $146.7 million increase in gain on the sale of assets, (ii) a $122.1 million decrease in the write-off of non-cash revenue (primarily straight-line revenue), (iii) $62.2 million in revenue from incremental new investments completed, and (iv) a $9.9 million increase in income from unconsolidated joint ventures. The increase in net income was partially offset by (i) a $29.8 million increase in loss on early extinguishment of debt, (ii) a $9.9 million increase in interest expense, and (iii) a $9.4 million increase in depreciation and amortization expense from new investments.

Net income for the three and nine months ended September 30, 2021 includes revenue recognized related to the application of security deposits and letter of credit proceeds, as well as revenue recognized based upon our ability to offset uncollected contractual rental obligations due from an operator against the interest and principal of certain Omega debt obligations.

THIRD QUARTER 2021 RESULTS

Revenues – Revenues for the quarter ended September 30, 2021 totaled $281.7 million, which included $12.1 million of straight-line and other non-cash revenue, $9.3 million of revenue related to the application of security deposits and letters of credit proceeds, $6.5 million of revenue recognized based on our ability to offset uncollected rent due from an operator against the interest and principal of certain debt obligations of Omega, $5.9 million of non-recurring revenue, and $3.6 million of real estate tax and ground rents, which were partially offset by a $2.2 million write-off of straight-line and other non-cash revenue.


Expenses – Expenses for the quarter ended September 30, 2021 totaled $194.2 million, primarily consisting of $86.1 million of depreciation and amortization expense, $55.8 million of interest expense, a $25.5 million provision for estimated current expected credit losses (“CECL”), $9.3 million of general and administrative (“G&A”) expense, $5.7 million of stock-based compensation expense, $4.9 million of impairment on real estate properties, $3.6 million of real estate tax and ground lease expense, and $3.2 million of amortized deferred financing costs.

Other Income and Expense – Other income and expense for the quarter ended September 30, 2021 totaled $54.8 million, which included $56.2 million of gain on assets sold, which was offset by $0.8 million of other expense and $0.6 million in charges related to the early extinguishment of debt obligations.

Funds From Operations – Nareit FFO for the quarter ended September 30, 2021 was $180.7 million, or $0.73 per common share, on 246.6 million weighted-average common shares outstanding, compared to $15.1 million, or $0.06 per common share, on 234.6 million weighted-average common shares outstanding, for the same period in 2020.

The $180.7 million of Nareit FFO includes a $2.2 million write-off of non-cash straight-line revenue, a $25.5 million provision for CECL, $9.3 million of revenue related to the application of security deposits and letters of credit proceeds, $6.5 million of revenue recognized based on our ability to offset uncollected rent due from an operator against the interest and principal of certain Omega debt obligations, $5.7 million of non-cash stock-based compensation expense, and a $0.6 million loss on early extinguishment of debt, which were partially offset by $5.9 million of non-recurring revenue.

The $15.1 million of Nareit FFO for the quarter ended September 30, 2020 included a $143.3 million write-off of non-cash revenue, a $32.1 million provision for credit losses, $5.1 million of non-cash stock-based compensation expense, a $1.6 million provision for uncollectible receivables related to an unconsolidated joint venture, a $1.2 million loss on early extinguishment of debt related to an unconsolidated joint venture, a $0.9 million loss on extinguishment of debt and $0.9 million in severance expense offset by $8.1 million of non-recurring revenue and a $0.3 million recovery on direct financing leases.

Adjusted FFO was $208.8 million, or $0.85 per common share, for the quarter ended September 30, 2021, compared to $191.8 million, or $0.82 per common share, for the same quarter in 2020. For further information, see the “Funds From Operations” schedule below and on the Company’s website.

FINANCING ACTIVITIES

ATM Programs and Dividend Reinvestment and Common Stock Purchase Plan – During the quarter ended September 30, 2021, the Company sold 1.3 million shares of its common stock under its 2021 ATM Program and its Dividend Reinvestment and Common Stock Purchase Plan. Aggregate gross proceeds from these sales generated $48.5 million in the third quarter and $279.6 million year-to-date:

At-the-Market Programs for 2021

(in thousands, except price per share)

Q1

Q2

Q3

Total

Number of shares

1,617

2,497

37

4,151

Average price per share

$

37.95

$

37.00

$

36.53

$

37.37

Gross proceeds

$

61,355

$

92,402

$

1,354

$

155,111

Dividend Reinvestment and Common Stock Purchase Plan for 2021

(in thousands, except price per share)

Q1

Q2

Q3

Total

Number of shares

416

1,640

1,279

3,335

Average price per share

$

37.23

$

37.69

$

36.88

$

37.32

Gross proceeds

$

15,491

$

61,795

$

47,178

$

124,464


2021 RECENT AND THIRD QUARTER PORTFOLIO ACTIVITY

Q4 2021 Portfolio Activity:

Guardian – In October 2021, Guardian Healthcare (“Guardian”) failed to make contractual rent and interest payments under its lease and mortgage loan agreements. Guardian represents 3.7% of Omega’s third quarter 2021 contractual rent and interest. Omega is in active discussions to transition a significant portion of this portfolio to an unrelated third party but has not reached any agreement. Omega holds letters of credit from Guardian equal to $7.4 million.

Q3 2021 Portfolio Activity:

Agemo – Agemo Holdings, LLC (“Agemo”) failed to pay contractual rent and interest to Omega from August 2021 through October. During August and September 2021, the Company recorded $8.4 million of revenue by drawing on Agemo’s letters of credit and through application of Agemo’s security deposit. Additionally, the Company recorded an aggregate provision for credit loss of $16.7 million on a $25.0 million working capital loan and a $32.0 million term loan with Agemo to reduce the value of these loans to the fair value of the collateral.

Gulf Coast – In June of 2021, Gulf Coast Health Care, LLC (together with certain affiliates “Gulf Coast”) stopped paying contractual rent under its master lease agreement for 24 facilities and the Company placed it on a cash basis of revenue recognition. In the third quarter, the Company recorded $7.4 million of revenue related to Gulf Coast through application of its security deposit and based on Omega’s ability to offset its uncollected contractual rent against the interest and principal of certain debt obligations of Omega. On October 14, 2021, Gulf Coast commenced voluntary cases under chapter 11 of the United States Bankruptcy Code. The Company has entered into a restructuring support agreement with Gulf Coast and has agreed to provide up to $25 million in senior secured debtor-in-possession financing, subject to certain conditions, to provide liquidity and assist with the transition of operations in the Company’s 24 facilities.

$172 Million of Real Estate Investments – In the third quarter of 2021, the Company completed approximately $66.0 million of mortgage loan investments, $9.6 million of real estate acquisitions, $15.8 million in capital renovations and $80.1 million of new construction projects, consisting of the following:

$66 Million Mortgage Loan – On July 1, 2021, the Company financed six skilled nursing facilities in Ohio and amended an existing $6.4 million mortgage to include the six facilities in a consolidated $72.4 million mortgage for eight Ohio facilities bearing interest at an initial rate of 10.5% per annum.

$10 Million Real Estate Acquisition – On July 14, 2021, the Company acquired two care home facilities (similar to assisted living facilities (“ALFs”) in the United States) located in the United Kingdom from an unrelated third party for approximately $9.6 million. The two facilities with 80 beds were added to an existing operator’s master lease with an initial annual cash yield of 8.0% with 2.5% annual escalators.

$80 Million of Construction-in-progress – In the third quarter of 2021, the Company invested $80.1 million under its construction-in-progress programs. This includes the purchase of a real estate property located in Washington, D.C. for approximately $68.0 million that Omega, in conjunction with Maplewood Senior Living, plans to redevelop into a 174-bed ALF and lease back to Maplewood Senior Living.

$16 Million of Capital Renovations – In the third quarter of 2021, the Company invested $15.8 million under its capital renovation programs.

Asset Sales and Impairments:

$110 Million in Asset Sales – In the third quarter of 2021, the Company sold 15 facilities for $109.7 million in cash, recognizing a gain of approximately $56.2 million.  Seven of these assets were previously classified as held for sale.


Impairments and Assets Held for Sale – During the third quarter of 2021, the Company recorded a net impairment charge of $4.9 million to reduce the net book value of six facilities to their estimated fair values or expected selling prices.

As of September 30, 2021, the Company had 11 facilities classified as assets held for sale, totaling approximately $21.5 million.

BALANCE SHEET AND LIQUIDITY

As of September 30, 2021, the Company had $5.3 billion of outstanding indebtedness with a weighted-average annual interest rate of 4.19%.  The Company’s indebtedness consisted of an aggregate principal amount of $4.9 billion of senior unsecured notes, a $50.0 million unsecured term loan, and $364.0 million of secured debt.  As of September 30, 2021, total cash and cash equivalents were $102.7 million and the Company had its full $1.45 billion of undrawn capacity on its revolving credit facility.

DIVIDENDS

On October 25, 2021, the Board of Directors declared a quarterly cash dividend of $0.67 per share, to be paid November 15, 2021, to common stockholders of record as of the close of business on November 5, 2021.

CONFERENCE CALL

The Company will be conducting a conference call on Friday, November 5, 2021 at 10 a.m. Eastern time to review the Company’s 2021 third quarter results and current developments.  Analysts and investors within the United States interested in participating are invited to call (877) 511-2891.  The Canadian toll-free dial-in number is (855) 669-9657.  All other international participants may use the dial-in number (412) 902-4140.  Ask the operator to be connected to the “Omega Healthcare’s Third Quarter 2021 Earnings Call.”

To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “Omega Healthcare Investors, Inc. 3Q Earnings Call” hyper link under “Upcoming Events” in the Investor Relations section on Omega’s website homepage.  Webcast replays of the call will be available on Omega’s website for approximately two weeks following the call.  Additionally, a copy of the earnings release will be available in the “Featured Documents” and “Press Releases” sections of Omega’s website.

* * * * * *

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure.  The assets span all regions within the United States, as well as in the United Kingdom.

FOR FURTHER INFORMATION, CONTACT

Matthew Gourmand, SVP, Corporate Strategy & Investor Relations

or

Bob Stephenson, CFO at (410) 427-1700



Forward-Looking Statements and Cautionary Language

Novel coronavirus (“COVID-19”) data has been provided by our operators. We caution that we have not independently validated facility virus incidence information, it may be reported on an inconsistent basis by our operators, and we can provide no assurance regarding its accuracy or that there have not been any changes since the time the information was obtained from our operators; we also undertake no duty to update this information.

This press release includes forward-looking statements within the meaning of the federal securities laws. All statements regarding Omega’s or its tenants', operators', borrowers' or managers' expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a real estate investment trust (“REIT”), plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations.

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of COVID-19 on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs, staffing shortages and decreased occupancy levels experienced by operators of SNFs and assisted living facilities (“ALFs”) in connection therewith, the ability of operators to comply with infection control and vaccine protocols, the long-term impact of vaccinations on facility infection rates, and the extent to which continued government support may be available to operators to offset such costs and the conditions related thereto; (iii) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations, and other costs and uncertainties associated with operator bankruptcies; (iv) Omega’s ability to re-lease, otherwise transition or sell underperforming assets or assets held for sale on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (v) the availability and cost of capital to us; (vi) changes in Omega’s credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) competition in the long-term healthcare industry and shifts in the perception of various types of long-term care facilities, including SNFs and ALFs; (ix) additional regulatory and other changes in the healthcare sector; (x) changes in the financial position of our operators; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) changes in interest rates; (xiii) the timing, amount and yield of any additional investments; (xiv) changes in tax laws and regulations affecting REITs; (xv) the potential impact of changes in the SNF and ALF market or local real estate conditions on the Company’s ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; (xvi) Omega’s ability to maintain its status as a REIT; (xvii) the effect of other factors affecting our business or the businesses of our operators that are beyond our or their control, including natural disasters, other health crises or pandemics and governmental action, particularly in the healthcare industry, and (xviii) other factors identified in Omega’s filings with the SEC.  Statements regarding future events and developments and Omega’s future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements.

We caution you that the foregoing list of important factors may not contain all the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.


OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

September 30, 

December 31, 

    

2021

    

2020

(Unaudited)

ASSETS

Real estate properties

Real estate investments

$

9,268,967

$

8,702,154

Less accumulated depreciation

 

(2,174,546)

 

(1,996,914)

Real estate investments – net

 

7,094,421

 

6,705,240

Investments in direct financing leases – net

 

10,762

 

10,764

Mortgage notes receivable – net

 

873,737

 

885,313

 

7,978,920

 

7,601,317

Other investments – net

 

434,028

 

467,442

Investments in unconsolidated joint ventures

 

193,741

 

200,638

Assets held for sale

 

21,528

 

81,452

Total investments

 

8,628,217

 

8,350,849

Cash and cash equivalents

 

102,664

 

163,535

Restricted cash

 

3,341

 

4,023

Contractual receivables – net

 

16,658

 

10,408

Other receivables and lease inducements

 

236,964

 

234,666

Goodwill

 

651,354

 

651,737

Other assets

 

140,751

 

82,231

Total assets

$

9,779,949

$

9,497,449

LIABILITIES AND EQUITY

 

  

Revolving credit facility

$

$

101,158

Secured borrowings

 

363,963

 

369,524

Senior notes and other unsecured borrowings – net

 

4,909,090

 

4,698,570

Accrued expenses and other liabilities

 

260,630

 

280,824

Deferred income taxes

 

8,798

 

10,766

Total liabilities

 

5,542,481

 

5,460,842

Equity:

 

  

Preferred stock $1.00 par value authorized – 20,000 shares, issued and outstanding – none

Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 238,939 shares as of September 30, 2021 and 231,199 as of December 31, 2020

 

23,893

 

23,119

Additional paid-in capital

 

6,425,720

 

6,152,887

Cumulative net earnings

 

2,978,183

 

2,594,735

Cumulative dividends paid

 

(5,393,284)

 

(4,916,097)

Accumulated other comprehensive income (loss)

 

1,476

 

(12,768)

Total stockholders’ equity

 

4,035,988

 

3,841,876

Noncontrolling interest

 

201,480

 

194,731

Total equity

 

4,237,468

 

4,036,607

Total liabilities and equity

$

9,779,949

$

9,497,449


OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands, except per share amounts)

Three Months Ended

 

Nine Months Ended

September 30, 

 

September 30, 

    

2021

    

2020

 

2021

    

2020

Revenues

 

  

 

  

  

 

  

Rental income

$

243,583

$

81,207

$

696,408

$

516,735

Real estate tax and ground lease income

 

3,581

 

2,019

 

9,472

9,523

Income from direct financing leases

 

257

 

258

 

772

 

775

Mortgage interest income

 

23,047

 

24,013

 

70,693

 

65,378

Other investment income

 

10,780

 

11,286

 

34,245

 

32,870

Miscellaneous income

 

424

 

394

 

1,270

 

3,315

Total revenues

 

281,672

 

119,177

 

812,860

 

628,596

Expenses

 

  

 

  

 

  

 

  

Depreciation and amortization

 

86,097

 

81,072

 

256,745

 

247,301

General and administrative

 

9,299

 

9,328

 

28,721

 

29,238

Real estate tax and ground lease expense

 

3,639

 

2,489

 

10,092

 

10,534

Stock-based compensation expense

 

5,706

 

5,122

 

16,913

 

14,380

Acquisition, merger and transition related costs

 

 

36

 

1,814

 

62

Impairment on real estate properties

 

4,942

 

28,105

 

42,453

 

43,732

Recovery on direct financing leases

 

 

(324)

 

(717)

 

(1,076)

Provision for credit losses

 

25,511

 

32,076

 

28,023

 

33,577

Interest expense

 

55,827

 

51,800

 

167,254

 

157,332

Interest – amortization of deferred financing costs

 

3,152

 

2,462

 

9,125

 

7,384

Total expenses

 

194,173

 

212,166

 

560,423

 

542,464

Other income (expense)

 

  

 

  

 

  

 

  

Other expense – net

 

(749)

 

(82)

 

(666)

 

(675)

Loss on debt extinguishment

 

(642)

 

(896)

 

(30,707)

 

(896)

Realized (loss) gain on foreign exchange

 

(18)

 

19

 

670

 

(50)

Gain (loss) on assets sold – net

 

56,169

 

(749)

 

160,634

 

13,932

Total other income (expense)

 

54,760

 

(1,708)

 

129,931

 

12,311

Income (loss) before income tax expense and income from unconsolidated joint ventures

 

142,259

 

(94,697)

 

382,368

 

98,443

Income tax expense

 

(976)

 

(763)

 

(2,873)

 

(2,626)

Income from unconsolidated joint ventures

 

1,552

 

1,692

 

14,569

 

4,654

Net income (loss)

 

142,835

 

(93,768)

 

394,064

 

100,471

Net (income) loss attributable to noncontrolling interest

 

(3,888)

 

2,477

 

(10,616)

 

(2,540)

Net income (loss) available to common stockholders

$

138,947

$

(91,291)

$

383,448

$

97,931

Earnings per common share available to common stockholders:

 

  

 

  

 

  

 

  

Basic:

 

  

 

  

 

  

 

  

Net income (loss) available to common stockholders

$

0.58

$

(0.40)

$

1.62

$

0.43

Diluted:

 

  

 

  

 

  

 

  

Net income (loss)

$

0.58

$

(0.40)

$

1.62

$

0.43

Dividends declared per common share

$

0.67

$

0.67

$

2.01

$

2.01


OMEGA HEALTHCARE INVESTORS, INC.

FUNDS FROM OPERATIONS

Unaudited

(in thousands, except per share amounts)

Three Months Ended

 

Nine Months Ended

September 30, 

 

September 30, 

2021

    

2020

 

2021

    

2020

Net income (loss) (1)(2)

$

142,835

$

(93,768)

$

394,064

$

100,471

(Deduct gain) add back loss from real estate dispositions

(56,169)

749

(160,634)

(13,932)

Add back loss (deduct gain) from real estate dispositions of unconsolidated joint ventures

 

2

 

(4,483)

 

(14,745)

 

(6,438)

Sub-total

 

86,668

 

(97,502)

 

218,685

 

80,101

Elimination of non-cash items included in net income:

 

  

 

  

 

  

 

  

Depreciation and amortization

 

86,097

 

81,072

 

256,745

 

247,301

Depreciation - unconsolidated joint ventures

 

2,951

 

3,379

 

9,379

 

10,561

Add back provision for impairments on real estate properties

 

4,942

 

28,105

 

42,453

 

43,732

Add back provision for impairments on real estate properties of unconsolidated joint ventures

 

 

 

4,430

 

Add back unrealized loss on warrants

 

 

87

 

43

 

927

Nareit funds from operations (“Nareit FFO”)

$

180,658

$

15,141

$

531,735

$

382,622

Weighted-average common shares outstanding, basic

 

239,282

 

227,507

 

236,027

 

227,393

Restricted stock and PRSUs

 

634

 

904

 

903

 

1,065

Omega OP Units

 

6,701

 

6,168

 

6,547

 

6,078

Weighted-average common shares outstanding, diluted

 

246,617

 

234,579

 

243,477

 

234,536

Nareit funds from operations available per share

$

0.73

$

0.06

$

2.18

$

1.63

Adjustments to calculate adjusted funds from operations:

 

  

 

  

 

  

 

  

Nareit FFO

$

180,658

$

15,141

$

531,735

$

382,622

Add back

Uncollectible accounts receivable (3)

 

2,206

 

143,296

 

22,357

 

144,501

Provision for credit losses

 

25,511

 

32,076

 

28,023

 

33,577

Stock-based compensation expense

 

5,706

 

5,122

 

16,913

 

14,380

Loss on debt extinguishment

642

896

30,707

896

Acquisition, merger and transition related costs

 

 

36

 

1,814

 

62

Severance

853

853

Deduct

Non-recurring revenue

 

(5,909)

 

(8,113)

 

(11,914)

 

(11,941)

Recovery on direct financing leases

 

 

(324)

 

(717)

 

(1,076)

Add back unconsolidated joint venture related

Uncollectible accounts receivable (3)

1,584

1,584

Loss on debt extinguishment

1,227

457

2,425

Adjusted funds from operations (“AFFO”) (1)(2)

$

208,814

$

191,794

$

619,375

$

567,883

Adjustments to calculate funds available for distribution:

 

  

 

  

 

  

 

  

Non-cash interest expense

$

2,102

$

2,440

$

6,152

$

7,316

Capitalized interest

 

 

(2,608)

 

(804)

 

(9,708)

Non-cash revenue

 

(12,125)

 

(8,288)

 

(35,751)

 

(28,786)

Funds available for distribution (“FAD”) (1)(2)

$

198,791

$

183,338

$

588,972

$

536,705


(1)The three and nine months ended September 30, 2021 includes the application of $9.3 million and $11.7 million, respectively, of Agemo and Gulf Coast security deposits (letter of credit and cash deposits) in revenue.
(2)The three and nine months ended September 30, 2021 includes $6.5 million of revenue related to Gulf Coast recognized based on our ability to offset uncollected rent against the interest and principal (in the fourth quarter) of certain debt obligations of Omega.
(3)Straight-line accounts receivable write-off recorded as a reduction to Rental income.


Nareit Funds From Operations (“Nareit FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures.  For purposes of the Securities and Exchange Commission’s Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the income statement, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented.  As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America.  Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports Nareit FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“Nareit”), and consequently, Nareit FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures and changes in the fair value of warrants. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. Revenue recognized based on the application of security deposits and letters of credit or based on the ability to offset against other financial instruments is included within Nareit FFO. The Company believes that Nareit FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance.  Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions.  The term funds from operations was designed by the real estate industry to address this issue.  Funds from operations described herein is not necessarily comparable to funds from operations of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as Nareit FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items (e.g., acquisition, merger and transition related costs, write-off of straight-line accounts receivable, recoveries and provisions for current expected credit losses, severance, etc.). FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD may not be comparable to the Nareit definition of funds from operations or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business.  The Company also uses FAD among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs, and which may be of limited relevance in evaluating current performance, funds from operations can facilitate comparisons of operating performance between periods and between other REITs.  The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP.  Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.


The following tables present selected portfolio information, including operator and geographic concentrations, and lease and loan maturities:

As of September 30, 2021

    

Total

    

# of

# of

Balance Sheet Data

Total # of

Investment

% of

Operating

Operating

Facilities

($000’s)

Investment

Facilities (2)

Beds (2)

Real estate investments (1)

 

887

$

9,279,729

91

%  

883

89,515

Mortgage notes receivable

 

65

 

873,737

9

%  

61

6,567

 

952

$

10,153,466

100

%  

944

96,082

Assets held for sale

 

11

 

21,528

  

 

  

  

Total investments

 

963

$

10,174,994

  

 

  

  

    

As of September 30, 2021

Total

# of

# of

Investment

Investment Data

Total # of

Investment

% of

Operating

Operating

per Bed

Facilities

($000’s)

Investment

Facilities (2)

Beds (2)

($000’s)

SNFs/Transitional care (1)

 

795

$

7,879,070

78

%  

787

84,993

$

93

Senior housing (3)

 

157

 

2,274,396

22

%  

157

11,089

$

205

 

952

$

10,153,466

100

%  

944

96,082

$

106

Assets held for sale

 

11

 

21,528

Total investments

 

963

$

10,174,994


(1) Includes one facility under a direct financing lease totaling $10.8 million.

(2) Excludes facilities which are non-operating, closed and/or not currently providing patient services.

(3) Includes ALFs, memory care and independent living facilities.

Revenue by Investment Type (000's)

Three Months Ended

Nine Months Ended

September 30, 2021

    

September 30, 2021

Rental property

    

$

243,840

    

87

%

$

697,180

    

86

%

Real estate tax and ground lease income

3,581

1

%

9,472

1

%

Mortgage notes

 

23,047

 

8

%

 

70,693

 

9

%

Other investment income and miscellaneous income - net

 

11,204

 

4

%

 

35,515

 

4

%

$

281,672

 

100

%

$

812,860

 

100

%

Revenue by Facility Type (000's)

Three Months Ended

Nine Months Ended

    

September 30, 2021

    

September 30, 2021

SNFs/Transitional care

$

217,964

    

77

%

    

$

627,948

    

77

%

Senior housing

 

48,923

 

18

%

 

139,925

 

17

%

Real estate tax and ground lease income

 

3,581

 

1

%

 

9,472

 

1

%

Other

 

11,204

 

4

%

 

35,515

 

5

%

$

281,672

 

100

%

$

812,860

 

100

%


    

As of

2021 Q3

% of Total

September 30, 2021

Annualized

Annualized

Rent/Interest Concentration by Operator ($000’s)

# of

Contractual

Contractual

Facilities (1)

Rent/Interest (1)(2)

Rent/Interest 

Ciena

 

64

$

97,560

 

10.1

%

Consulate

 

85

 

94,910

 

9.8

%

Maplewood

 

17

 

66,875

 

6.9

%

Communicare

 

43

 

64,231

 

6.6

%

Genesis

 

44

 

55,314

 

5.7

%

Agemo

 

51

 

53,106

 

5.5

%

Saber

 

50

 

52,693

 

5.4

%

Brookdale

 

24

 

44,484

 

4.6

%

HHC

 

44

 

37,640

 

3.9

%

Guardian

 

35

 

36,916

 

3.8

%

Remaining Operators (3)

 

463

 

366,652

 

37.7

%

 

920

$

970,381

 

100.0

%


(1) Excludes facilities which are non-operating, closed and/or not currently providing patient services.

(2) Includes mezzanine and term loan interest.

(3) Excludes one multi-tenant medical office building and 23 facilities related to an operator that declared bankruptcy in October 2021.

As of September 30, 2021

Geographic Concentration by Investment ($000’s)

    

Total # of

Total

% of Total

Facilities (1)

Investment (1)(2)

Investment

Florida

 

133

$

1,553,597

 

15.3

%

Texas

 

114

 

993,481

 

9.7

%

Michigan

 

46

 

646,478

 

6.3

%

Indiana

 

70

 

640,554

 

6.3

%

California

 

53

 

581,541

 

5.7

%

Ohio

 

46

 

568,127

 

5.6

%

Pennsylvania

 

48

 

547,067

 

5.4

%

Virginia

 

28

 

421,378

 

4.1

%

New York

 

1

 

335,710

 

3.3

%

North Carolina

 

39

 

327,645

 

3.2

%

Remaining 32 states

 

315

 

3,130,039

 

30.7

%

 

893

 

9,745,617

 

95.6

%

United Kingdom

 

59

 

445,586

 

4.4

%

 

952

$

10,191,203

 

100.0

%


(1) Excludes 11 facilities with total investment of approximately $21.5 million classified as assets held for sale.

(2) Excludes $37.8 million of allowance for credit losses.

As of September 30, 2021

Operating Lease Expirations & Loan Maturities ($000's) (1)

Lease (Rent)

Interest Income

Lease (Rent) and Interest Income

% of Total Annualized Contractual Rent/Interest

2021

$

3,428

$

$

3,428

 

0.4

%

2022

 

 

44

 

44

 

0.0

%

2023

 

3,800

 

598

 

4,398

 

0.5

%

2024

 

4,099

 

7,330

 

11,429

 

1.2

%

2025

 

5,034

 

5,296

 

10,330

 

1.1

%


(1) Based on annualized 3rd quarter 2021 contractual rent and interest.


The following tables present operator revenue mix, census and coverage data based on information provided by our operators for the indicated periods.  We have not independently verified this information, and we are providing this data for informational purposes only.

Operator Revenue Mix (1)

    

  

Medicare /

Private /

Medicaid

Insurance

Other

Three-months ended June 30, 2021

 

53.2

%  

33.5

%  

13.3

%

Three-months ended March 31, 2021

 

50.6

%  

38.2

%  

11.2

%

Three-months ended December 31, 2020

 

51.0

%  

38.1

%  

10.9

%

Three-months ended September 30, 2020

 

51.6

%  

37.2

%  

11.2

%

Three-months ended June 30, 2020

 

52.4

%  

36.4

%  

11.2

%


(1) Excludes all facilities considered non-core.

Coverage Data

    

    

Before

After

Occupancy (2)

Management

Management

Operator Census and Coverage (1)

Fees (3)

Fees (4)

Twelve-months ended June 30, 2021

 

74.2

%  

1.63x

1.28x

Twelve-months ended March 31, 2021

 

75.3

%  

1.80x

1.44x

Twelve-months ended December 31, 2020

 

78.1

%  

1.86x

1.50x

Twelve-months ended September 30, 2020

 

80.1

%  

1.87x

1.51x

Twelve-months ended June 30, 2020

 

82.2

%  

1.84x

1.48x


(1)

Excludes facilities considered non-core.

(2)

Based on available (operating) beds.

(3)

Represents EBITDARM of our operators, defined as earnings before interest, taxes, depreciation, amortization, Rent expense and management fees for the applicable period, divided by the total Rent payable to the Company by its operators during such period. “Rent” refers to the total monthly rent and mortgage interest due under the Company’s lease and mortgage agreements over the applicable period.

(4)

Represents EBITDAR of our operators, defined as earnings before interest, taxes, depreciation, amortization, and Rent (as defined in footnote 3) expense for the applicable period, divided by the total Rent payable to the Company by its operators during such period. Assumes a management fee of 4%.

The following table presents a debt maturity schedule as of September 30, 2021:

Unsecured Debt

Debt Maturities ($000’s)

Revolving Credit Facility and OP Term Loan (1)

Senior Notes (1)

Subordinated
 Notes

Secured Debt

Total Debt Maturities

2021

$

$

$

20,000

$

$

20,000

2022

 

 

 

2,275

 

2,275

2023

 

 

350,000

 

 

350,000

2024

 

 

400,000

 

 

400,000

2025

 

50,000

 

400,000

 

 

450,000

2026

 

 

600,000

 

 

600,000

Thereafter

 

 

3,150,000

 

361,688

 

3,511,688

$

50,000

$

4,900,000

$

20,000

$

363,963

$

5,333,963


(1) Excludes issuance and deferred financing costs.


The following table presents real estate investment activity:

Three Months Ended

Nine Months Ended

Real Estate Investment Activity ($000's)

September 30, 2021

September 30, 2021

$ Amount

    

%

    

$ Amount

    

%

Real property

$

9,617

5.6

%

$

604,121

73.7

%

Construction-in-progress

80,125

 

46.7

%

109,047

 

13.3

%

Capital expenditures

 

15,819

 

9.2

%

 

34,787

 

4.2

%

Mortgages

66,000

38.5

%

72,420

8.8

%

Other

 

 

%

 

 

%

Total

$

171,561

 

100.0

%

$

820,375

 

100.0

%


GRAPHIC 3 ohi-20211104ex99119fc24001.jpg GRAPHIC begin 644 ohi-20211104ex99119fc24001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HJ MCJFLZ;HEJ;G4[V&UA[-*V,GT ZD_2N9A^*WA">X\E=1=>07'^K<$^AX-0,GHHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "L+Q=XE@\*:!-J,JB23.R"+./, MD/0?3N?85NUXY\:)Y)=5TJSS^Z2%Y,_=0?W5'85WOPR\ PZRQUG58=]C&VV"%NDS#J3ZJ/3N?I M7!K <<#GM7T[H5C'IF@V%E$H588$7 ]<,JNG348:7.:BN>5V+>:=$ M\.Z&)5D1<*%& 0.U(AJ,C64[#[0HW(W]\=_Q%='7D>AB6WUJRG!.Y9E'X$X/Z&O7*;$96 MO^(M,\,Z:U_JEP(H@<*H&6D;T4=S7-P:YXWU^ 76D:)8:;9N-T3ZG*QE<=CL M3[N?.*)ONE8@2>/\ :9>?; KW:NBI!44DU=O4 MS3YK]CRG5O'/CCPA,DGB#0["XLF8 3VC,J_3)S@_45VWA7QCI7BZR:;3W99H M\":WDX>,_P!1[BMB^LK;4K&:RO(5FMYD*21L.&!KYPA:Y^'7Q*,:2,4M;@1M M_P!-8'QU_P" D'ZBM:=.&(BTE:2_$4FX/R/;?%.L>(O#]E=ZI:V5A?6, WM' MO>.54[GN#CD]N*Y_P1\4V\4^(O[+N["*S\R)FA9)"Q9AR5.0.V3^%=?XP(_X M0K6SV^PS'_QPUX;XGT2;PA/X:\1:6NR.>V@F![+.J L#[,.?^^J,/3IU(.,E M[W1A-N+NMCZ-H) &2<5GZ'K%MK^B6FJ6IS%<1AP.ZGNI]P/3EU'=^Z4.[0XX^\< YZ]!Z5X1INGV^E?&V MVL+5-EO;ZAY<:^BA.*^BZZL5"$'%06ZN9TVW>YY'-\6M;@\0-H1T"S_M 7(M M?^/IMA2ZBN_XXE1WUB+_T):^BZK$Q MA34>6*U5P@W*]V<=XTRRM!!:B=7MI&'G?')^F0/SK.G2]M4Y4K=QRERQN=O;_$35 MO$MY)!X/\/FYAB;#WM])Y40_ <_AG/M6@]Q\1K6/S38^'[WN88I9(V^@+<9K MI-"T:UT#1;73+1 L4"!<@23CG@ ULZ!JT>N:! M8ZI& %N85D('\)(Y'X'(KS/XAV%UXRUC4[6S=C!X>LO.(7D27#_,4_[X7\ZE M^".O"XTJ\T.1\O;-Y\()ZQMU'X-_Z%72Z"^K\ZW6_HS-3?/;H>L5 LS&^DA. M-JQJP]
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end EX-101.SCH 4 ohi-20211104.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ohi-20211104_lab.xml EX-101.LAB EX-101.PRE 6 ohi-20211104_pre.xml EX-101.PRE XML 7 ohi-20211104x8k_htm.xml IDEA: XBRL DOCUMENT 0000888491 2021-11-04 2021-11-04 0000888491 false 8-K 2021-11-04 OMEGA HEALTHCARE INVESTORS, INC. MD 1-11316 38-3041398 303 International Circle, Suite 200 Hunt Valley MD 21030 410 427-1700 false false false false false Common Stock OHI NYSE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 04, 2021
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 04, 2021
Entity Registrant Name OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key 0000888491
Entity Incorporation, State or Country Code MD
Entity File Number 1-11316
Entity Tax Identification Number 38-3041398
Amendment Flag false
Entity Emerging Growth Company false
Entity Address, Address Line One 303 International Circle,
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Title of 12(b) Security Common Stock
Trading Symbol OHI
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ohi-20211104x8k.htm ohi-20211104.xsd ohi-20211104_lab.xml ohi-20211104_pre.xml ohi-20211104ex99119fc24.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ohi-20211104x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ohi-20211104x8k.htm" ] }, "labelLink": { "local": [ "ohi-20211104_lab.xml" ] }, "presentationLink": { "local": [ "ohi-20211104_pre.xml" ] }, "schema": { "local": [ "ohi-20211104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ohi", "nsuri": "http://www.omegahealthcare.com/20211104", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20211104x8k.htm", "contextRef": "Duration_11_4_2021_To_11_4_2021_JVgU55ZWLk2D0RfbU75BgA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20211104x8k.htm", "contextRef": "Duration_11_4_2021_To_11_4_2021_JVgU55ZWLk2D0RfbU75BgA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000888491-21-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000888491-21-000024-xbrl.zip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end